Related Experiment Videos
Inactivated virosome hepatitis A vaccine
L Loutan1, P Bovier, B Althaus
1Department of Medicine, Hôpital Cantonal Universitaire de Genève, Switzerland.
Lancet (London, England)
|February 5, 1994
Summary
A novel Hepatitis A Virus (HAV) vaccine using immunopotentiating reconstituted influenza virosomes (IRIV) demonstrated high efficacy and safety. A single dose achieved 98% seroconversion, with sustained immunity and a significant booster response one year later.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Hepatitis A virus (HAV) poses a significant public health concern.
- Developing effective and safe vaccine delivery systems is crucial for disease prevention.
- Immunopotentiating reconstituted influenza virosomes (IRIV) show promise as carriers for viral antigens.
Purpose of the Study:
- To evaluate the immunogenicity and tolerability of an IRIV-HAV vaccine.
- To assess the effectiveness of a booster dose of the IRIV-HAV vaccine.
- To determine the safety profile of the IRIV-HAV vaccine in healthy volunteers.
Main Methods:
- A clinical trial involving 104 healthy, HAV-seronegative volunteers.
- Administration of a single dose of the IRIV-HAV vaccine.
- Assessment of anti-HAV antibody titers at baseline, 2 weeks, 1 year, and 1 month post-booster.
- Monitoring for adverse reactions.
Main Results:
- A single dose of the IRIV-HAV vaccine resulted in 98% seroconversion within 2 weeks.
- High anti-HAV titers were maintained, with 100% seroconversion one year post-vaccination.
- A booster dose 1 year later induced a 22-fold increase in geometric mean titers (GMT) within 1 month.
- No serious adverse reactions were reported during the study.
Conclusions:
- The IRIV-HAV vaccine is highly immunogenic and well-tolerated in healthy adults.
- The vaccine provides sustained protection and a robust response to a booster dose.
- IRIV technology offers an effective platform for HAV vaccine development.